Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build
01:10am, Monday, 18'th May 2026
Incyte NASDAQ: INCY President and CEO Bill Meury said the company's post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business
Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
07:20pm, Wednesday, 13'th May 2026
Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
09:30am, Tuesday, 12'th May 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adult
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 06'th May 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Why Incyte (INCY) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 06'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Incyte (INCY) is a Strong Growth Stock
10:45am, Tuesday, 05'th May 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 04'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
12:00pm, Sunday, 03'rd May 2026
/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics is pleased to announce that NIKTIMVO (axatilimab) has been approved for use in
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatm
Incyte to Present at Upcoming Investor Conferences
08:00am, Wednesday, 29'th Apr 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conferences.
Incyte Corporation (INCY) Q1 2026 Earnings Call Transcript
02:21pm, Tuesday, 28'th Apr 2026
Incyte Corporation (INCY) Q1 2026 Earnings Call Transcript
INCY Q1 Earnings and Revenues Beat Estimates on Higher Product Sales
01:03pm, Tuesday, 28'th Apr 2026
Incyte tops Q1 estimates with $1.27 billion in revenues and strong earnings, fueled by Jakafi growth and rising Opzelura demand.
Compared to Estimates, Incyte (INCY) Q1 Earnings: A Look at Key Metrics
10:31am, Tuesday, 28'th Apr 2026
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street e
Incyte beats first-quarter estimates on strong demand for cancer drugs
10:01am, Tuesday, 28'th Apr 2026
Drugmaker Incyte beat analysts' estimates for first-quarter profit and revenue on Tuesday, partly helped by strong demand for its cancer treatments, including Jakafi and Minjuvi.
